Tuesday, April 11, 2023
CENTOGENE announced it has extended its partnership with Takeda to diagnose patients with Lysosomal Storage Disorders (LSDs).
Under the renewed one-year partnership agreement, CENTOGENE will continue to provide Takeda with access to diagnostic testing for patients around the world. The aim of the commercial fee-for-service agreement is to enhance patient access to rapid and reliable diagnostics for LSDs, including Fabry disease, Gaucher disease, and Hunter syndrome.
This expanded partnership with Takeda accelerates diagnosis and increase access to life-saving therapeutics for patients globally. This collaboration continues to play a vital role in the expansion of Takeda’s world-class enzyme replacement treatments and most importantly, brings life-changing answers to underserved patient communities.
